Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme’s Myozyme meets co-primary efficacy endpoints
The study enrolled 90 patients at eight primary sites in the US and Europe. Participants received either Myozyme or a placebo every other week for 18 months. The
The study enrolled 90 patients at eight primary sites in the US and Europe. Participants received either Myozyme or a placebo every other week for 18 months. The
In this study, investigators used Nutrition 21’s proprietary chromium picolinate found in Core4Life Advanced Memory Formula, a nutritional supplement specifically formulated to improve brain health. Study participants were
Kuvan is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia due to tetrahydrobiopterin responsive phenylketonuria (PKU) and is to be used in conjunction with a
This placebo controlled, double blind safety extension trial is designed to collect longer-term use patient safety data in support of the company’s submission of a new drug application
The partnership is part of the Stallergenes ‘Enhanced Allergens’ innovation program for a recombinant protein treatment for sublingual desensitisation of allergy to mites. This second-generation treatment is made
Under terms of the non-exclusive licensing arrangement, Hemispherx will receive both royalties as well as income for all Ampligen supplies used in both the ongoing experimental work and
The sNDA is based on efficacy and safety data in more than 670 patients with advanced-stage Parkinson’s disease who were treated with rotigotine in three double-blind, placebo-controlled clinical
In this open label trial, each patient will receive eight weekly infusions of ofatumumab. The first infusion will be 300mg and the seven subsequent infusions will be 1000mg
This recommendation follows the data safety monitoring board’s (DSMB) review of the blinded data from the first one-third of the 830 patients to be enrolled in two ongoing
Alnylam’s Phase I study for ALN-RSV01 was a randomized, double-blind, placebo-controlled trial in healthy adult volunteers to assess the safety, tolerability, and pharmacokinetics of ALN-RSV01 administrated by inhalation